Compare · ACAD vs JNJ
ACAD vs JNJ
Side-by-side comparison of ACADIA Pharmaceuticals Inc. (ACAD) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACAD and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $611.90B, about 184.5x ACAD ($3.32B).
- Over the past year, ACAD is down 7.1% and JNJ is up 33.0% - JNJ leads by 40.1 points.
- JNJ has been more active in the news (16 items in the past 4 weeks vs 4 for ACAD).
- Both have 25 recent analyst ratings on file.
- Company
- ACADIA Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $19.14-2.87%
- $255.53+0.88%
- Market cap
- $3.32B
- $611.90B
- 1M return
- -30.32%
- -5.45%
- 1Y return
- -7.07%
- +33.03%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1985
- News (4w)
- 4
- 16
- Recent ratings
- 25
- 25
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ACAD
- ACADIA Pharmaceuticals downgraded by UBS with a new price target
- Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
- ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
- SEC Form 8-K filed by ACADIA Pharmaceuticals Inc.
- European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
- EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. exercised 20,141 shares at a strike of $17.84 and sold $587,242 worth of shares (20,141 units at $29.16) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by ACADIA Pharmaceuticals Inc.
- ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause